Ocata Therapeutics (OCAT) Stock Price, News & Analysis

Company Overview

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Key Stats

• Today's Range: $8.47 to $8.47
• 50-Day Range: N/A
• 52-Week Range: $3.06 to $8.71
• Volume: N/A
• Average Volume: 656,469 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OCAT Stock Analysis - Frequently Asked Questions

How were Ocata Therapeutics' earnings last quarter?

Ocata Therapeutics (NASDAQ:OCAT) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company earned $0.04 million during the quarter.

What other stocks do shareholders of Ocata Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ocata Therapeutics investors own include Antares Pharma (ATRS), Anavex Life Sciences (AVXL), Sarepta Therapeutics (SRPT), Athersys (ATHX), Prospect Capital (PSEC), Bristol Myers Squibb (BMY) and Conatus Pharmaceuticals (CNAT).

Company Calendar

• Last Earnings: 8/06/2015
• Today: 8/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OCAT
• Previous Symbol: OTCMKTS:ACTC
• CIK: 1140098
• Web: www.ocata.com
• Phone: +1-508-7561212
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A